Among pediatric acute lymphoblastic leukemia patients who have favorable prognosis, an attempt to reduce the burden of chemotherapy by using lower intensity delayed intensification failed to show better outcomes.

Source: CancerNetworkCategory: Cancer & Oncology Authors: Tags: Conferences/ASH 2016 News Pediatric Cancers Source Type: news

Related Links:

Conclusion: Silymarin decreased early Doxorubicin induced left ventricular systolic function disturbances and can be recommended as adjuvant drug in patients with ALL under doxorubicin therapy.
RECOMMENDATION: Multicenter studies on large number of patients with longer duration of follow up to prove the protective effects of silymarin in early and late Doxorubicin induced cardiotoxicity.
PMID: 30073931 [PubMed – as supplied by publisher]

Source: Infectious Disorders Drug TargetsCategory: Infectious Diseases Authors: Tags: Infect Disord Drug Targets Source Type: research

Secondary malignancies are broadly defined as a group of cancers arising after a previous malignancy and have become increasingly appreciated due to improvement in cancer survival. Therapy-related malignancies are a sub-group of secondary malignancies in which the exposure to prior chemotherapy or radiation therapy is instrumental to the establishment of the secondary cancer. Other than the role of previous therapies, underlying genetic predisposition, immunodeficiency states or simple coincidence have all also been invoked as potential causative factors for the development of secondary cancers [1].

Source: Leukemia ResearchCategory: Hematology Authors: Source Type: research

CONCLUSION: Multiple ALL chemotherapy agents can affect postnatal brain development or heart function. This study provides a ranking of agents based on potential toxicity, and thus highlights a subset likely to cause side effects in early adulthood for further study.
PMID: 30054283 [PubMed – as supplied by publisher]

Source: Clinical Cancer ResearchCategory: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research

Authors: Niedźwiecki M, Budziło O, Zieliński M, Adamkiewicz-Drożyńska E, Maciejka-Kembłowska L, Szczepański T, Trzonkowski P
Abstract
CD4+CD25highCD127low/-FoxP3+ regulatory T cells (Tregs) are currently under extensive investigation in childhood acute lymphoblastic leukemia (ALL) and in other human cancers. Usually, Treg cells maintain the immune cell homeostasis. This small subset of T cells has been, in fact, considered to be involved in the pathogenesis of autoimmune diseases and progression of acute and chronic leukemias. However, whether Treg dysregulation in CLL and ALL plays a key role or it rather r…

AbstractImmunotherapy has played an important part in improving the life of patients with lymphoproliferative diseases especially since the addition of rituximab to chemotherapy in the CD20-positive neoplasms in the 1990s. While this field of passive immunotherapy is continuously evolving, several breakthroughs will expand the treatment modalities to include more active immunotherapy. With the approval of immune checkpoint-blocking antibodies for Hodgkin lymphoma and bispecific antibodies for acute lymphoblastic leukemia (ALL), activation of endogenous T cells already plays a role in several lymphoid malignancies. With the…

Publication date: 9 July 2018Source: Cancer Cell, Volume 34, Issue 1Author(s): Chelsea L. Dieck, Gannie Tzoneva, Farhad Forouhar, Zachary Carpenter, Alberto Ambesi-Impiombato, Marta Sánchez-Martín, Renate Kirschner-Schwabe, Scott Lew, Jayaraman Seetharaman, Liang Tong, Adolfo A. FerrandoSummaryActivating mutations in the cytosolic 5′-nucleotidase II gene NT5C2 drive resistance to 6-mercaptopurine in acute lymphoblastic leukemia. Here we demonstrate that constitutively active NT5C2 mutations K359Q and L375F reconfigure the catalytic center for substrate access and catalysis in the absence of allosteric a…

Source: Cancer CellCategory: Cancer & Oncology Source Type: research

Induction chemotherapy results in high remission rate in high risk (HR) and very high risk (VHR) childhood acute lymphoblastic leukemia (ALL), but is associated with significant morbidity [1,2]. HR B-ALL is defined as: white blood cell count (WBC) ≥50,000/µL or age ≥10 years (National Cancer Institute (NCI) criteria) at presentation, or/and central nervous system (CNS) positive leukemia, or testicular leukemia [3–5]. Patients who are>13 years or experience induction failures; and/or if the leukemia blasts harbor mixed-lineage leukemia gene (MLL) rearrangements or intrachromosomal amplification of chrom…

Source: Leukemia ResearchCategory: Hematology Authors: Tags: Research paper Source Type: research

In the phase 3 TOWER study, blinatumomab significantly improved overall survival in adults with relapsed or refractory (R/R) Philadelphia chromosome–negative (Ph–) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) relative to standard-of-care chemotherapy. A secondary objective of this study was to assess the impact of blinatumomab on health-related quality of life (HRQL) as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30). This analysis included the 342 of 405 randomized patients for whom baseline and ≥1 postbaseline result were…

Source: BloodCategory: Hematology Authors: Tags: Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research

Considerable improvements have been seen during the last decades in the development of effective treatment protocols for childhood cancer, which usually consist of multiagent chemotherapy (CH), radiotherapy, or a combination of both. For example, the cure rate for Acute Lymphoblastic Leukemia (ALL), which is the most common childhood malignancy [1], has increased from less than 30% during the 1960s to an 80 –86% 5-year overall survival [2].

Source: Oral OncologyCategory: Cancer & Oncology Authors: Tags: Review Source Type: research

Conclusion: The delay in the diagnosis of MA-HLH in pediatric patients may be due to decrease awareness about the condition the timely diagnosis of MA-HLH is crucial for a better outcome. Herein, we discuss our experience with this rare entity in pediatric oncology patients with review of literature.





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here